Top Stories
The company said ERAS-0015 monotherapy recorded responses in pancreatic, lung and biliary tract tumours as combination work also advances.
Updated Phase I/II results point to durable benefit with first-line chemotherapy combination.
The TROP2-directed antibody-drug conjugate significantly improved survival versus standard treatment in patients with locally advanced unresectable or metastatic gastroesophageal adenocarcinoma who have received two or more prior lines of systemic therapy.
Arcera gains exclusive rights across emerging markets, including Latin America and the Middle East.
The agreement will see the companies combine their resources to hunt for small-molecule drug candidates targeting oncology.
Conference News
48% confirmed overall response rate (ORR) with a 10.4-month median duration of response in the primary analysis population of 65 patients with platinum-resistant/refractory ovarian cancer 36% ORR wit...
From early antibody hits to engineered formats and antibody–oligonucleotide conjugates, Tsingke helps R&D teams generate the data they need to make the next development decision.LISBON, Portugal, Nov....
Safety profile to date with continuous daily dosing supports continued dose optimization and clinical development Pharmacodynamic data demonstrate WEE1 target engagement across multiple doses, pharmac...
TREMFYA showed statistically significant improvement in disease activity on the BASDAI score versus placebo, reflecting meaningful reductions in pain, stiffness, swelling and fatigue in a Phase 4 stud...
Company to Host In-Person Event at ASH 2026 Featuring New Market Research and a Physician Panel Discussion on Barriers to CAR T Access, Community Adoption in Large B-Cell Lymphoma (LBCL), and the Pote...



